The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.

Conference activity picks up, with the big one – ASCO – at the end of the month.

Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.

A key pivotal study of bemarituzumab will read out shortly.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

AstraZeneca bags three of the month’s four oncology approvals.

The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.

The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.

The synthetic lethality specialist licenses in its second ADC in six months.